Listing code
113.06
Children (Part B)
Body system
113.00
Cancer (malignant neoplastic diseases, children)
Subsections
2
Lettered criteria paths
Step in evaluation
3 of 5
Listing match approves the claim
SSA listing text and criteria
Leukemia (See 113.00K2 )
Subsection A
Acute leukemia (including all types of lymphoblastic lymphoma and juvenile chronic myelogenous leukemia (JCML). Consider under a disability until at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system. OR
Subsection B
Chronic myelogenous leukemia (except JCML), as described in 1 or 2: 1. Accelerated or blast phase (see 113.00K2b ). Consider under a disability until at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system. 2. Chronic phase, as described in a or b: a. Consider under a disability until at least 12 months from the date of bone marrow or stem cell transplantation. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system. b. Progressive disease following initial anticancer therapy.
- Accelerated or blast phase (see 113.00K2b ). Consider under a disability until at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system.
- Chronic phase, as described in a or b:
Source: SSA Blue Book listing 113.06. Last synced 2026-05-04.
Where claims under 113.06 usually fail
One pitfall is treating any leukemia in a child as automatically covered without separating acute leukemia (113.06A) from chronic myelogenous leukemia, which has its own phase-based rules in 113.06B. Another pitfall is missing the disease-phase timing concepts in 113.06B, like 'accelerated or blast phase' versus 'chronic phase' and 'progressive disease following initial anticancer therapy.' A third pitfall is assuming coverage continues indefinitely after diagnosis; 113.06A and 113.06B both require counting from the diagnosis or relapse date and/or from the date of bone marrow or stem cell transplantation, with different minimum time periods. A fourth pitfall is forgetting that after the required time period ends, ongoing impairments are evaluated under the criteria for the affected body system rather than by 113.06 alone.
Medical evidence that strengthens this claim
Medical evidence needs to specify the type, extent, and site of the primary, recurrent, or metastatic lesion. For operative procedures such as biopsy or needle aspiration, SSA generally needs both an operative note and a pathology report. When those documents cannot be obtained, summaries of hospitalization(s) or other medical reports can be accepted, and they should include surgical findings and, when appropriate, pathological findings. In some situations, SSA may also need evidence about recurrence, persistence, or progression of the cancer, response to therapy, and significant residuals, which matters for the 113.06B timing and phase concepts like blast/accelerated phase and progressive disease after initial anticancer therapy.
What happens if your records do not meet this listing
If the diagnosis does not fit the lettered patterns in 113.06A or 113.06B (for example, the subtype and phase are not established as acute leukemia or as CML in an accelerated/blast phase or chronic phase with the required conditions), the case does not satisfy this specific listing. SSA then proceeds to the later steps of the disability decision process, which includes assessing functional limits through residual functional capacity and evaluating how the child can function despite the cancer and any treatment effects. Even when the exact listing criteria are not met, medical evidence of persistence, progression, or significant residual impairments can still be relevant because any residual impairments after the listing time period are evaluated under criteria for the affected body system.
Work activity and the SGA gate for this condition
For a child claim, SSA still needs to determine whether the condition meets the listing criteria in 113.06 based on acute leukemia (113.06A) or chronic myelogenous leukemia phases and progression rules (113.06B). The listing provides specific disability time periods that depend on whether the child is within at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later for acute leukemia and for certain CML situations. The same structure applies for the CML chronic phase rule, including the requirement of at least 12 months from the date of bone marrow or stem cell transplantation, and also for chronic phase progressive disease following initial anticancer therapy. After these minimum time periods, any residual impairment(s) must be evaluated under the criteria for the affected body system.
Listing 113.06 FAQ
Questions that come up repeatedly for leukemia disability claims.